Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SNAP goes from food to mood

Synaptic Pharmaceutical Corp. has been developing SNAP-7941 to treat obesity. Now, the company has reported in Nature Medicine that the compound also might be useful to treat anxiety and depression.

SNAP's rationale for developing

Read the full 339 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE